TITLE

Molecular farming of recombinant antibodies in plants

AUTHOR(S)
Schillberg, S.; Fischer, R.; Emans, N.
PUB. DATE
March 2003
SOURCE
Cellular & Molecular Life Sciences;Mar2003, Vol. 60 Issue 3, p433
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
: Antibodies represent a large proportion of therapeutic drugs currently in development. In most cases, they are produced in mammalian cell lines or transgenic animals because these have been shown to fold and assemble the proteins correctly and generate authentic glycosylation patterns. However, such expression systems are expensive, difficult to scale up and there are safety concerns due to potential contamination with pathogenic organisms or oncogenic DNA sequences. Plants represent an inexpensive, efficient and safe alternative for the production of recombinant antibodies. Research over the last 10 years has shown that plants can produce a variety of functional antibodies and there is now intense interest in scaling up production to commercial levels. In this review, we discuss the advantages of plants over traditional expression systems, describe how antibody expression in plants is achieved and optimized and then consider the practical issues concerning large-scale molecular farming in plants. The first plant-produced therapeutic antibodies are already in clinical trials, and, given the economic benefits of this production system, we are likely to see many more recombinant antibodies produced in this manner in the future.
ACCESSION #
15728756

 

Related Articles

  • Transgenic Tobacco Plants Producing Human Interleukin-18. Turchinovich, A. A.; Deineko, E. V.; Filipenko, M. L.; Khrapov, E. A.; Zagorskaya, A. A.; Filipenko, E. A.; Sennikov, S. V.; Kozlov, V. A.; Shumnyi, V. K. // Doklady Biochemistry & Biophysics;Mar/Apr2004, Vol. 395 Issue 1-6, p104 

    Presents a study which focused on transgenic tobacco plant which produces human interleukin (IL)-18. Information on recombinant proteins produced by transgenic plants; Details of the development of transgenic tobacco plants producing human IL-18; Information on the target gene used in plant...

  • Plastoglobules: a new address for targeting recombinant proteins in the chloroplast. Vidi, Pierre-Alexandre; Kessler, Felix; Brehelin, Claire // BMC Biotechnology;2007, Vol. 7, p4 

    Background: The potential of transgenic plants for cost-effective production of pharmaceutical molecules is now becoming apparent. Plants have the advantage over established fermentation systems (bacterial, yeast or animal cell cultures) to circumvent the risk of pathogen contamination, to be...

  • Overexpression of a Single-Chain Variable Fragment (scFv) Antibody Confers Unstable Resistance to TuMV in Chinese Cabbage. Zhao, Mei-Ai; An, Song-Ji; Lee, Suk-Chan; Kim, Do-Sun; Kang, Byoung-Cheorl // Plant Molecular Biology Reporter;Dec2013, Vol. 31 Issue 6, p1203 

    A single-chain variable fragment ( scFv) antibody is a recombinant protein composed of immunogloblin fused to a flexible linker protein. Recent studies have demonstrated that transfer of scFv to plants is effective in engineering virus resistance in plants. In this study, the utility of scFv in...

  • DNA-Delivery Methods to Produce Transgenic Plants. Darbani, Behrooz; Farajnia, Safar; Toorchi, Mahmoud; Zakerbostanabad, Saeed; Noeparvar, Shahin; Stewart Jr., C. Neal // Biotechnology;2008, Vol. 7 Issue 3, p385 

    Since the 1980s, diverse methods for plant transformation have been described including biological, chemical and physical based methods. Transformation is performed to introduce novel traits, study basic biological processes, or produce recombinant proteins of interest. We review...

  • Increased yield of heterologous viral glycoprotein in the seeds of homozygous transgenic tobacco plants cultivated underground. Tackaberry, Eilleen S.; Prior, Fiona; Bell, Margaret; Tocchi, Monika; Porter, Suzanne; Mehnic, Jelica; Ganz, Peter R.; Sardana, Ravinder; Altosaar, Illimar; Dudani, Anil // Genome;Jun2003, Vol. 46 Issue 3, p521 

    The use of transgenic plants in the production of recombinant proteins for human therapy, including subunit vaccines, is being investigated to evaluate the efficacy and safety of these emerging biopharmaceutical products. We have previously shown that synthesis of recombinant glycoprotein B (gB)...

  • Production of recombinant proteins in plant root exudates. Borisjuk, Nikolai V.; Borisjuk, Ludmyla G.; Logendra, Sithes; Petersen, Frank; Gleba, Yuri; Raskin, Ilya // Nature Biotechnology;May99, Vol. 17 Issue 5, p466 

    The large-scale production of recombinant proteins in plants is limited by relatively low yields and difficulties in extraction and purification. These problems were addressed by engineering tobacco plants to continuously secrete recombinant proteins from their roots into a simple hydroponic...

  • The Bush administration deals a blow to biotechnology?and itself. Miller, Henry I. // Nature Biotechnology;Sep2001, Vol. 19 Issue 9, p807 

    Examines federal regulation in the biotechnology sector in the United States. Regulation of recombinant plants; Policy of the Environmental Protection Agency; Occupational exposures to toxic chemicals.

  • Detection of genetically modified plant products by protein strip testing: an evaluation of real-life samples. Marc Van den Bulcke; Adinda De Schrijver; Daniele De Bernardi; Yann Devos; Guillaume MbongoMbella; Amaya Leunda Casi; William Moens; Myriam Sneyers // European Food Research & Technology;May2007, Vol. 225 Issue 1, p49 

    Abstract  The determination of the presence of genetically modified plant material by the detection of expressed genetically engineered proteins using lateral flow protein strip tests has been evaluated in different matrices. The presence of five major genetically engineered proteins...

  • Cytoprotective Effect of Recombinant Human Erythropoietin Produced in Transgenic Tobacco Plants. Kittur, Farooqahmed S.; Bah, Mamudou; Archer-Hartmann, Stephanie; Hung, Chiu-Yueh; Azadi, Parastoo; Ishihara, Mayumi; Sane, David C.; Xie, Jiahua // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Asialo-erythropoietin, a desialylated form of human erythropoietin (EPO) lacking hematopoietic activity, is receiving increased attention because of its broader protective effects in preclinical models of tissue injury. However, attempts to translate its protective effects into clinical practice...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics